Literature DB >> 15758135

Alteplase stability and bioactivity after low-power ultrasonic energy delivery with the OmniSonics resolution system.

John Smikahl1, Doug Yeung, Sharon Wang, Charles P Semba.   

Abstract

PURPOSE: Low-power ultrasonic (US) energy is capable of clot dissolution in vivo. The combination of US energy plus alteplase may further accelerate clot lysis; however, the effects of cavitation could potentially denature and inactivate the lytic protein. The purpose of this study was to determine the bioactivity and stability of alteplase when exposed to US energy with use of a novel intravascular US wire in an in vitro model.
MATERIALS AND METHODS: The model consisted of a 6.4-mm-diameter silicone tube closed at one end and filled with alteplase (1 mg/mL) in a water bath (37 degrees C). A 95-cm US wire (0.025-inch diameter, 20 kHz) was inserted into the tube and connected to a variable power generator. The wire delivers low-power acoustic energy 360 degrees around its 20-cm active length and was irrigated by a continuous infusion of purified water. Fresh 6-mL alteplase aliquots were exposed to US energy and tested in duplicates. Zero (control), 1 W, or 2 W of energy was delivered to individual test samples for zero (control), 0.5, 3, or 6 minutes. Alteplase samples were assayed for optical clarity and protein concentration with use of UV spectrophotometry, for percent protein monomer with use of high-performance size-exclusion chromatography, and for in vitro clot lysis activity.
RESULTS: In the control samples, optical clarity was clear or colorless in all samples; protein concentration was 1.02 mg/mL +/- 0; protein monomer was 98%; and clot lysis activity was 108% per mg +/- 1. In the test samples, optical clarity was clear or colorless in all samples; protein concentrations at 0.5, 3, and 6 minutes were 0.98 mg/mL +/- 0.02, 0.93 mg/mL +/- 0.01, and 0.86 mg/mL +/- 0.02, respectively, at 1 W, and 1.00 mg/mL +/- 0.03, 0.94 mg/mL +/- 0.10, and 0.84 mg/mL +/- 0.17, respectively, at 2 W. Protein monomer was 98% for all samples. Clot lysis activity levels at 0.5, 3, and 6 minutes were 111% per mg +/- 1, 110% per mg +/- 1, and 115% per mg +/- 1, respectively, at 1 W, and 110% per mg +/- 0, 111% per mg +/- 1, and 116% per mg +/- 2, respectively, at 2 W.
CONCLUSIONS: Alteplase solutions exposed to low-power US energy for as long as 6 minutes remained fully active and stable as determined by protein assays. Further investigation is warranted with use of combinations of US energy and alteplase.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15758135     DOI: 10.1097/01.RVI.0000147066.97599.87

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  4 in total

1.  Helicopter "Drip and Ship" Flights Do Not Alter the Pharmacological Integrity of rtPA.

Authors:  Brett A Faine; Sanjana Dayal; Rahul Kumar; Steven R Lentz; Enrique C Leira
Journal:  J Stroke Cerebrovasc Dis       Date:  2018-07-20       Impact factor: 2.136

2.  Preclinical testing of a new clot-retrieving wire device using polyvinyl alcohol hydrogel vascular models.

Authors:  Fumio Asakura; Hasan Yilmaz; German Abdo; Lucka Sekoranja; Diego San Millan; Luca Augsburger; Roman Sztajzel; Daniel A Ruefenacht; Fabienne Perren; Karl-Olof Lovblad; Katsuya Goto
Journal:  Neuroradiology       Date:  2006-11-23       Impact factor: 2.804

3.  Ultrasound-triggered release of recombinant tissue-type plasminogen activator from echogenic liposomes.

Authors:  Denise A B Smith; Sampada S Vaidya; Jonathan A Kopechek; Shao-Ling Huang; Melvin E Klegerman; David D McPherson; Christy K Holland
Journal:  Ultrasound Med Biol       Date:  2010-01       Impact factor: 2.998

4.  Stability of alteplase for ultrasound-facilitated catheter-directed thrombolysis.

Authors:  John Fanikos; Kathleen Marquis; Leo Buckley; Lena K Tran; Kevin McLaughlin; Abby Jane Golash; Umberto Campia; Gregory Piazza; Jean M Connors; Samuel Z Goldhaber
Journal:  Blood Adv       Date:  2021-12-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.